SCHEMBL1990376

SCHEMBL1990376

COc1ccc(Br)cc1CBr

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.56
TDP1 Q9NUW8 3/20 0.56
LMNA P02545 2/20 0.54
ALDH1A1 P00352 3/20 0.53
KMT2A Q03164 3/20 0.53
MEN1 O00255 2/20 0.53
USP2 O75604 1/20 0.53
GAA P10253 1/20 0.53
MAPT P10636 1/20 0.53
THRB P10828 1/20 0.53
ALOX15 P16050 1/20 0.53
CASP1 P29466 1/20 0.53
HTT P42858 1/20 0.53
RECQL P46063 1/20 0.53
BLM P54132 1/20 0.53
HSD17B10 Q99714 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.49
POLB P06746 1/20 0.47
MC4R P32245 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30036793 1.00 KDM4E (0.56) KDM4ETDP1LMNAALDH1A1KMT2A
SCHEMBL6488941 0.84 KDM4E (0.53) KDM4ETDP1LMNAALDH1A1KMT2A
SCHEMBL31469118 0.84 KDM4E (0.53) KDM4ETDP1LMNAALDH1A1KMT2A
SCHEMBL1125103 0.83 PYCR1 (0.53) KDM4ETDP1LMNAALDH1A1KMT2A
SCHEMBL3991296 0.83 KDM4E (0.56) KDM4ETDP1LMNAALDH1A1KMT2A
SCHEMBL30423333 0.83 PYCR1 (0.53) KDM4ETDP1LMNAALDH1A1KMT2A
SCHEMBL31288205 0.83 KDM4E (0.56) KDM4ETDP1LMNAALDH1A1KMT2A
SCHEMBL3484667 0.82 LMNA (0.54) KDM4ETDP1LMNAALDH1A1KMT2A
SCHEMBL1145684 0.82 PTGDR2 (0.57) KDM4ETDP1LMNAALDH1A1KMT2A
SCHEMBL7975482 0.82 KDM4E (0.54) KDM4ETDP1LMNAALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250282786-A1 Tricyclic TLR7 Agonists and Uses Thereof BRISTOL-MYERS SQUIBB COMPANY (US) 2025-09-11 US disclosed
WO-2025108255-A1 POLYCYCLIC DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF 上海齐鲁制药研究中心有限公司 2025-05-30 WO disclosed
US-20250073236-A1 PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS APROS THERAPEUTICS INC (US) 2025-03-06 US disclosed
CN-110177780-B Pyrimidine compounds containing acidic groups 阿普罗斯治疗公司 2022-11-01 CN disclosed
EP-4058435-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE Genentech, Inc. (US) 2022-09-21 EP disclosed
US-20220281819-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE GENENTECH, INC. (US) 2022-09-08 US disclosed
CN-114728905-A Therapeutic compounds and methods of use 基因泰克公司 2022-07-08 CN disclosed
EP-3548478-B1 PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS APROS THERAPEUTICS INC (US) 2021-11-17 EP disclosed
US-11173157-B2 Substituted pyrimidines containing acidic groups as TLR7 modulators Apros Therapeutics, Inc. (US) 2021-11-16 US disclosed
EP-3137468-B1 COMPOUNDS AND COMPOSITIONS AS TOLL-LIKE RECEPTOR 7 AGONISTS NOVARTIS AG (CH) 2021-10-06 EP disclosed
WO-2006100208-A1 1-BENZYLINDOLE-2-CARBOXAMIDE DERIVATIVES N.V. ORGANON (NL) 2006-09-28 WO disclosed
EP-0889889-B1 PIPERAZINE AND PIPERIDINE COMPOUNDS DUPHAR INT RES (NL) 2006-09-20 EP disclosed
EP-1687299-A1 HETEROCYCLIC COMPOUNDS AS MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS, USEFUL FOR THE TREAMTMENT AND/OR PREVENTION OF DISORDERS MODULATED BY A PPAR ELI LILLY AND COMPANY (US) 2006-08-09 EP disclosed
EP-1590338-A2 MODULATORS OF MELANOCORTIN RECEPTOR Gene Logic Inc. (US) 2005-11-02 EP disclosed
WO-2005051945-A1 HETEROCYCLIC COMPOUNDS AS MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS, USEFUL FOR THE TREATMENT AND/OR PREVENTION OF DISORDERS MODULATED BY A PPAR ELI LILLY AND COMPANY (US) 2005-06-09 WO disclosed
US-20040147746-A1 Modulators of melanocortin receptor MILLENNIUM PHARMACEUTICALS, INC. 2004-07-29 US disclosed
WO-2004050610-A2 MODULATORS OF MELANOCORTIN RECEPTOR GENE LOGIC INC. (US) 2004-06-17 WO disclosed
US-6225312-B1 TREATING A CNS DISORDER SUCH AS SCHIZOPHRENIA DUPHAR INTERNATIONAL RESEARCH B.V. (NL) 2001-05-01 US disclosed
EP-0889889-A1 PIPERAZINE AND PIPERIDINE COMPOUNDS DUPHAR INTERNATIONAL RESEARCH B.V (NL) 1999-01-13 EP disclosed
WO-1997036893-A1 PIPERAZINE AND PIPERIDINE COMPOUNDS DUPHAR INTERNATIONAL RESEARCH B.V. (NL) 1997-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250282786-A1 Tricyclic TLR7 Agonists and Uses Thereof TLR7, TLR9, TLR1 KDM4E 3303/4885TDP1 627/4885LMNA 2840/4885
US-20220281819-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE VHL, NQO1, PCSK9 KDM4E 2745/4885TDP1 1486/4885LMNA 1651/4885
US-20040147746-A1 Modulators of melanocortin receptor MC1R, MC3R, MC5R KDM4E 2340/4885TDP1 4803/4885LMNA 3822/4885
US-20250073236-A1 PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS MAVS, TLR7, STING1 KDM4E 3029/4885TDP1 312/4885LMNA 4274/4885
US-11173157-B2 Substituted pyrimidines containing acidic groups as TLR7 modulators TLR7, TLR9, MAVS KDM4E 2050/4885TDP1 388/4885LMNA 4400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.